



Atty. Dkt. No. 065678-0108

1FW
K
CC

Applicant: Naoshi Fukushima, et al.

Title: AGONIST ANTIBODIES

Appl. No.: 10/645,085

Filing Date: 10/7/2002

Examiner: Bristol, Lynn Anne

Art Unit: 1643

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

03/30/2006 JADD01 00000010 10645085

01 FC:1806

180.00 00

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

An English abstract of the foreign-language document is provided. The absence of a full translation does not relieve the PTO from its duty to consider the submitted foreign language document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A credit card payment form in the amount of \$180.00 is enclosed in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.


Respectfully submitted,

Date 3/28/06

By 

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

for Stephen B. Maebius *Matthew McIlkenn*
Attorney for Applicant *Reg. No. 44,250*
Registration No. 35,264



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | |
|--|---|-------------------|---|
| Substitute for Form PTO/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | |
| Date Submitted: March 29, 2006 | | | |
| (use as many sheets as necessary) | | | |
| Sheet | 1 | of | 5 |
| Application Number | | 10/645,085 | |
| Filing Date | | 01/24/2003 | |
| First Named Inventor | | Naoshi Fukushima | |
| Group Art Unit | | 1643 | |
| Examiner Name | | Bristol, Lynn | |
| Attorney Docket Number | | 065678-0108 | |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| | | Number | Kind Code ² (if known) | | | |
| | C1 | 5,837,242 | | Holliger et al. | 11-17-1998 | |
| | C2 | 5,840,344 | | Fukushima | 11-24-1998 | |
| | C3 | 5,885,574 | | Elliott | 03-23-1999 | |
| | C4 | 6,719,972 | B1 | Gribben et al. | 04-13-2004 | |
| | C5 | 6,759,043 | B2 | Fukushima | 07-06-2004 | |
| | C6 | 6,579,692 | B1 | Fukushima | 06-17-2003 | |
| | C7 | 2003/0157100 | A1 | Fukushima et al. | 08-2003 | |
| | C8 | 2003/0211108 | A1 | Fukushima et al. | 11-2003 | |
| | C9 | 2003/0147894 | A1 | FUKUSHIMA et al. | 08/07/2003 | |
| | C10 | 2003/0157577 | A1 | Fukushima et al. | 08-2003 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|--|--|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | C11 | WO | 91/16928 | | Cell-Tech Limited | 11-14-1991 | | |
| | C12 | WO | 96/36360 | A | UNIV MINNESOTA | 11-21-1996 | | |
| | C13 | WO | 99/03495 | A | BETH ISRAEL HOSPITAL | 01-28-1999 | | |
| | C14 | WO | 99/10494 | | Genentech, Inc. | 03-04-1999 | | |
| | C15 | JP | 11-092500 | | Chugai Pharma. Co. Ltd. | 04-06-1999 | | A |
| | C16 | WO | 99/17364 | | Raytheon Company | 04-08-1999 | | |
| | C17 | EP | 1 035 132 | | Chugai Seiyaku Kabushiki Kaisha | 09-13-2000 | | |
| | C18 | WO | 02/078612 | A | PURDUE PHARMA LP | 10-10-2002 | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|---|----------------|
| | C19 | BARTLEY, T., et al., "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl," Cell, Vol. 77, pp. 1117-1124 (1994). | |
| | C20 | BAZIL, V., et al., "Apoptosis of Human Hematopoietic Progenitor Cells Induced by Crosslinking of Surface CD43, the Major Sialoglycoprotein of Leukocytes," pp. 502-511 (1995) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|-------------------------------|------------------|
| Substitute for form 1449B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/645,085 |
| | | | | Filing Date | 01/24/2003 |
| | | | | First Named Inventor | Naoshi Fukushima |
| | | | | Group Art Unit | 1643 |
| | | | | Examiner Name | Bristol, Lynn |
| Date Submitted: March 29, 2006 | | | | Attorney Docket Number | 065678-0108 |
| (use as many sheets as necessary) | | | | | |
| Sheet | 2 | of | 5 | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog; etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | C21 | BERGER, S. L., et al., "Inhibition of Intractable Nucleases with Ribonucleoside-Vanadyl Complexes: Isolation of Messenger Ribonucleic Acid From Resting Lymphocytes", <i>Biochemistry</i> , Vol. 18, No. 23, pp. 5143-5149 (1979) | |
| | C22 | BURTHEM, et al., "Hairy Cell Interactions with Extracellular Matrix: Expression of Specific Integrin Receptors and Their Role in the Cell's Response to Specific Adhesive Proteins," <i>Blood</i> , Vol. 84, No. 3, pp. 873-882 (1994). | |
| | C23 | CALDAS, C., et al., <i>Mol. Immunol.</i> , Vol. 39, No. 15, pp. 941-952 (2003). | |
| | C24 | CHIEN, N. C., et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 84, No. 14, pp. 5532-5536 (1989). | |
| | C25 | CHIRGWIN, J. M., et al., "Isolation of Biologically Active Ribonucleic Acid from Sources Enriched in Ribonuclease", <i>Biochemistry</i> , Vol. 18, No. 24, pp. 5294-5299 (1979). | |
| | C26 | COOPER, D., et al., "Transendothelial migration of neutrophils involves integrin-associated protein (CD47)," <i>Proc. Natl. Acad. Sci. USA</i> , pp. 3978-3982 (1995). | |
| | C27 | de SAUVAGE, F., et al., "Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the c-Mpl Ligand," <i>Nature</i> , Vol. 369, pp. 533-538 (1994). | |
| | C28 | de ST. GROTH, S. F., et al., "Production of Monoclonal Antibodies: Strategy and Tactics," <i>Journal of Immunological Methods</i> , Vol. 35, pp. 1-21 (1980) | |
| | C29 | DENG, B., et al., "An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis," <i>Blood</i> , Vol. 92, No. 6, pp. 1981-1988 (1991). | |
| | C30 | FELGENHAUER, M., et al., "Nucleotide Sequences of the cDNAs Encoding the V-Regions of H- and L-Chains of a Human Monoclonal Antibody Specific to HIV-1 - gp41," <i>Nucleic Acids Research</i> , Vol. 18, No. 16, p. 4927 (1990). | |
| | C31 | FUJIMOTO, T., et al., <i>Blood</i> , Vol. 86, No. 6, pp. 2174-2182 (1995). | |
| | C32 | FUKUSHIMA, N., et al., "Enhanced Hematopoiesis In Vivo and In Vitro by Splenic Stromal Cells Derived From the Mouse With Recombinant Granulocyte Colony-Stimulating Factor", <i>Blood</i> , Vol. 80, No. 8, pp. 1914-1922 (1992) | |
| | C33 | GALFRE, G., et al., "Preparation of Monoclonal Antibodies: Strategies and Procedures," <i>Methods in Enzymology</i> , Vol. 73, pp. 3-46 (1981) | |
| | C34 | GALFRE, G., et al., "Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG," <i>Nature</i> , Vol. 277, pp. 131-133 (1979) | |
| | C35 | GENESTIER, L., et al., "Antibodies to HLA Class I α 1 Domain Trigger Apoptosis of CD 40-Activated Human B Lymphocytes," <i>Blood</i> , Vol. 90, No. 2, pp. 726-735 (1997) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|-------------------------------|------------------|
| Substitute for form 1449B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/645,085 |
| | | | | Filing Date | 01/24/2003 |
| | | | | First Named Inventor | Naoshi Fukushima |
| | | | | Group Art Unit | 1643 |
| | | | | Examiner Name | Bristol, Lynn |
| Date Submitted: March 29, 2006 | | | | Attorney Docket Number | 065678-0108 |
| (use as many sheets as necessary) | | | | | |
| Sheet | 3 | of | 5 | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | C36 | GIUSTI, A. M., et al., Proc. Natl. Acad. Sci. USA, Vol. 84, No. 9, pp. 2926-2930 (1987). | |
| | C37 | GODING, Monoclonal Antibodies: Principles and Practice, Academic Press, second Ed, pp. 125-129 (1986) | |
| | C38 | GRELL, M., et al., "TR50 and TR80 Tumor Necrosis Factor (TNF)-Receptors Can Independently Mediate Cytolysis", Lymphokine and Cytokine Research, vol. 12, no. 3, pp. 143-148 (June 1993). | |
| | C39 | GUSSOW, D., et al., Methods in Enzymology, Vol. 203, pp. 99-121 (1991). | |
| | C40 | HOPP, T., et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," Bio/Technology, Vol. 6, pp. 1204-1210 (1988). | |
| | C41 | HUDSON, P. J., et al., "High avidity scFv multimers; diabodies and triabodies" J. Immunol. Methods, Elsevier Science Publishers, Vol. 231, No. 1-2, pp. 177-189 (1999). | |
| | C42 | HUSTON, J., et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in <i>Escherichia Coli</i> ," Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 5879-5883 (1988). | |
| | C43 | ITOH, N., et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," Cell, Vol. 66, pp. 233-243 (1991) | |
| | C44 | JIANG et al., "A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2," J. Biol. Chem., February 11, 2005, Vol. 280, No. 6, pp. 4656-4662. | |
| | C45 | KEARNEY, J. F., et al., "A New Mouse Myeloma Cell Line That Has Lost Immunoglobulin Expression But Permits The Construction of Antibody-Secreting Hybrid Cells Lines," The Journal of Immunology, Vol. 123, No. 4, pp. 1548-1550 (1979) | |
| | C46 | KIPRIYANOV, S., et al., "Bispecific CD3 X CD19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells," Int. J. Cancer, Vol. 77, pp. 763-772 (1988). | |
| | C47 | KOHLER, G., et al., "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," Eur. J. Immunol., Vol. 6, pp. 511-519 (1976) | |
| | C48 | LARRICK, J. W., et al., "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells", Bio/Technology, Vol. 7, pp. 934-938 (1989) | |
| | C49 | LAW, L. W., et al., "Observations On The Effect Of A Folic-Acid Anatagonist On Transplantable Lymphoid Leukemias In Mice", Journal of the National Cancer Institute, Vol. 10, pp. 179-193 (1949). | |
| | C50 | LEI, S. et al., "Characterization of the <i>Erwinia Carotovora pelB</i> Gene and Its Product Pectate Lyase," J. Bacteriol., pp. 4379-4383 (1987). | |
| | C51 | LINDBERG, et al., "Rh-Related Antigen CD47 is the Signal-Transducer Integrin-Associated Protein," J. Biol. Chem., Vol. 269, pp. 1567-1570 (1994). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 29, 2006 (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/645,085 |
| | | | | Filing Date | 01/24/2003 |
| | | | | First Named Inventor | Naoshi Fukushima |
| | | | | Group Art Unit | 1643 |
| | | | | Examiner Name | Bristol, Lynn |
| | | | | Attorney Docket Number | 065678-0108 |
| Sheet | 4 | of | 5 | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| | C52 | MARGULIES, D. H., et al., "Somatic Cell Hybridization of Mouse Myeloma Cells," Cell, Vol. 8, pp. 405-415 (1976) | |
| | C53 | MARIUZZA, R. A., et al., Annu. Rev. Biophys. Biophys. Chem., Vol. 16, pp. 139-159 (1987) | |
| | C54 | MAWBY, W. J., et al., "Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumor marker OA3," Biochem. J., Vol. 304, pp. 525-530 (1994) | |
| | C55 | METHIA, N., et al., "Oligodeoxynucleotides Antisense to the Proto-Oncogene <i>c-Mpl</i> Specifically Inhibit In Vitro Megakaryocytopoiesis," Blood, Vol. 82, No. 5, pp. 1395-1401 (1993). | |
| | C56 | MILILI, M., et al., "The VDJ Repertoire Expressed in Human preB Cells Reflects the Selection of <i>Bona Fide</i> Heavy Chains," Eur. J. Immunol., Vol. 26, pp. 63-69 (1996). | |
| | C57 | NAKAYAMA, et al., J. Mole. Med., Vol. 83, PP. 316-320 (2005). | |
| | C58 | PAUL, Fundamental Immunology, Raven Press, NY, Chapter 8, p. 242 (1993) | |
| | C59 | PETTERSON, "CD47 and death signaling in the immune system," Apoptosis Vol. 5, pp. 299-306 (2000) | |
| | C60 | REINHOLD et al., "In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)," J. Cell Science, 1995, vol. 108, pp. 3419-3425. | |
| | C61 | RIECHMANN, L., et al., "Reshaping Human Antibodies for Therapy", Nature, Vol. 332, pp. 323-327 (1988). | |
| | C62 | ROUE, G., et al., Biochimie, Vol. 85, pp. 741-746 (2003). | |
| | C63 | RUDIKOFF, et al., Proc. Natl. Acad. Sci. USA Vol. 79, p. 1979 (1982) | |
| | C64 | SCHICKEL, et al., "Gene for Integrin-Associated Protein (IAP, CD47): Physical Mapping, Genomic Structure, and Expression Studies in Skeletal Muscle," Biochem. Cell. Biol., Vol. 80, No. 2, pp. 169-176 (2002). | |
| | C65 | SCHWARTZ, M. A., et al., "A 50-kDa Integrin-associated Protein Is Required for Integrin-regulated Calcium Entry in endothelial Cells," J. Biol. Chem., Vol. 268, No. 27, pp. 19931-19934 (1993) | |
| | C66 | SHIGETA, M., et al., "Sperm-immobilizing monoclonal antibody to human seminal plasma antigens," Clin. Exp. Immunol., Vol. 42, pp. 458-462 (1980) | |
| | C67 | SHULMAN, M., et al., "A better cell line for making hybridomas secreting specific antibodies," Nature, Vol. 276, pp. 269-270 (1978) | |
| | C68 | SKOLNICK, et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era," Trends in Biotechnology, Vol. 18, pp. 34-39 (2000). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 29, 2006 <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/645,085 |
| | | | | Filing Date | 01/24/2003 |
| | | | | First Named Inventor | Naoshi Fukushima |
| | | | | Group Art Unit | 1643 |
| | | | | Examiner Name | Bristol, Lynn |
| | | | | Attorney Docket Number | 065678-0108 |
| Sheet | 5 | of | 5 | | |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|--|----------------|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ | |
| | C69 | SOUYRI, M., et al., "A Putative Truncated Cytokine Receptor Gene Transduced by the Myeloproliferative Leukemia Virus Immortalizes Hematopoietic Progenitors," Cell, Vol. 63, December 21, pp. 1137-1147 (1990). | | |
| | C70 | SPAARGAREN, M., et al., "Antibody-induced Dimerization Activates the Epidermal Growth Factor Receptor Tyrosine Kinase", The J. Biol. Chem., Vol. 266, No. 3, pp. 1733-1739 (1981). | | |
| | C71 | STANCOVSKI et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth," Proc. Natl. Acad. Sci. USA, October 1991, Vol. 88, pp. 8691-8695. | | |
| | C72 | TROWBRIDGE, I. S., "Interspecies Spleen-Myeloma Hybrid Producing Monoclonal Antibodies Against Mouse Lymphocyte Surface Glycoprotein, T200," J. Exp. Med., Vol. 148, pp. 313-323 (1978) | | |
| | C73 | XIE, et al, "Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv," Nature Biotechnology, Vol. 15, pp. 768-771 (1997). | | |
| | C74 | YELTON, D. E., et al., "Fusion of Mouse Myeloma and Spleen Cells," Current Topics in Microbiology and Immunology, Vol. 81, pp. 1-7 (1978) | | |
| | | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.